title: Human peripheral blood lymphocytes from recently vaccinated individuals produce both type-specific and intertypic cross-reacting neutralizing antibody on in vitro stimulation with one type of poliovirus.
abstract: An in vitro system of poliovirus-specific antibody production by peripheral blood B cells on stimulation by the virus has been developed. Virus-neutralizing antibodies in culture supernatant fluids, or virus-specific antibody-secreting cells (ASC) were detected by microneutralization assay and ELISA-SPOT test, respectively. After booster immunization with polio vaccine, anti-poliovirus-neutralizing ASC were present in circulation. This response was measurable between 5 and 12 days after booster vaccination. At between 12 and 90 days, another subset of B cells was found in peripheral blood that only produced poliovirus-specific neutralizing antibody after in vitro antigenic stimulation. The in vitro virus-induced response required B cells, monocytes, and T4+ (T helper) cells, and was shown to result from de novo protein synthesis. The anti-poliovirus-neutralizing response in vitro could be dissected in a type-specific and intertypic cross-reactive response by using various antigen concentrations for in vitro stimulation. Evidence was obtained by absorption studies for the existence of intertypic cross-reactive neutralization-inducing epitopes.
authors.forename: F G
authors.initials: FG
authors.lastname: Uytdehaag
authors.forename: H G
authors.initials: HG
authors.lastname: Loggen
authors.forename: T
authors.initials: T
authors.lastname: Logtenberg
authors.forename: R A
authors.initials: RA
authors.lastname: Lichtveld
authors.forename: B
authors.initials: B
authors.lastname: van Steenis
authors.forename: J A
authors.initials: JA
authors.lastname: van Asten
authors.forename: A D
authors.initials: AD
authors.lastname: Osterhaus
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000145:classification; D000918:Antibody Specificity; D001402:B-Lymphocytes / Q000145:classification / Q000276:immunology / Q000378:metabolism*; D003429:Cross Reactions; D004168:Diphtheria Toxoid / Q000008:administration & dosage; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D004338:Drug Combinations / Q000008:administration & dosage; D006801:Humans; D007700:Kinetics; D008213:Lymphocyte Activation; D008297:Male; D009500:Neutralization Tests; D010567:Pertussis Vaccine / Q000008:administration & dosage; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage* / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D013745:Tetanus Toxoid / Q000008:administration & dosage; D013997:Time Factors
chemical_list: D000914:Antibodies, Viral; D004168:Diphtheria Toxoid; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D004338:Drug Combinations; D010567:Pertussis Vaccine; D011054:Poliovirus Vaccine, Inactivated; D013745:Tetanus Toxoid